Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.99
-0.32 (-0.51%)
At close: Oct 30, 2026, 4:00 PM EDT
63.15
+0.16 (0.25%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Cytokinetics Employees
Cytokinetics had 673 employees as of December 31, 2025. The number of employees increased by 175 or 35.14% compared to the previous year. That makes Cytokinetics the 17,801st largest employer in the world and 2,448th in the United States.
Employees
673
Change (1Y)
175
Growth (1Y)
35.14%
Revenue / Employee
$100,550
Profits / Employee
-$1,328,383
Market Cap
8.76B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 673 | 175 | 35.14% |
| Dec 31, 2024 | 498 | 75 | 17.73% |
| Dec 31, 2023 | 423 | 14 | 3.42% |
| Dec 31, 2022 | 409 | 156 | 61.66% |
| Dec 31, 2021 | 253 | 69 | 37.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Twist Bioscience | 979 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| TG Therapeutics | 399 |
| Krystal Biotech | 295 |
CYTK News
- 11 days ago - Cytokinetics to Announce Third Quarter Results on November 4, 2026 - GlobeNewsWire
- 13 days ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 13 days ago - Cytokinetics price target lowered to $81 from $85 at BofA - TheFly
- 13 days ago - Cytokinetics announces Health Canada approval of Myqorzo for oHCM treatment - TheFly
- 13 days ago - Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 17 days ago - Cytokinetics initiated with an Outperform at William Blair - TheFly
- 18 days ago - Cytokinetics price target lowered to $104 from $115 at UBS - TheFly
- 20 days ago - Cytokinetics announces additional data from ACACIA-HCM trial at HFSA - TheFly